NasdaqGM:AQSTPharmaceuticals
Aquestive Therapeutics (AQST) Q1 Loss Per Share Narrows Challenging Bearish Narratives
Aquestive Therapeutics (AQST) opened Q1 2026 with revenue of US$14.4 million and a reported loss of US$8.1 million, equal to a basic EPS loss of US$0.07. The trailing twelve months show revenue of US$50.3 million and a net loss of US$68.9 million or EPS of US$0.61. Over recent quarters the company has reported revenue rising from US$8.7 million in Q1 2025 to US$14.4 million in Q1 2026, with quarterly EPS losses ranging from US$0.24 to US$0.26 through 2025 before narrowing to US$0.07 in the...